MK-8828
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $195,512 | 23 | 0 |
| 2017 | $17,506 | 4 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $212,643 | 26 | 99.8% |
| Consulting Fee | $375.00 | 1 | 0.2% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients | Merck Sharp & Dohme Corporation | $141,018 | 0 |
| A Multi-Center Non-Interventional Retrospective Study of the Use of Letermovir for the Treatment of Cytomegalovirus Disease or Infection in Solid Organ or Stem Cell Transplant Recipients Resistant, Refractory or Intolerant of Available Treatments | Merck Sharp & Dohme Corporation | $23,817 | 0 |
| Risk Factors for Valganciclovir-Associated Neutropenia in Kidney Transplant Recipients A Retrospective Study | Merck Sharp & Dohme Corporation | $16,910 | 0 |
| Cytomegalovirus infection and disease in a cohort of allogenic hematopoietic cell transplant recipients a comprehensive epidemiologic study of patients who underwent allogenic HCT over last 10 years | Merck Sharp & Dohme Corporation | $15,000 | 0 |
| A retrospective, case-control study to evaluate healthcare resource utilization and the clinical and economic burden of ganciclovir-resistant CMV infection in lung transplant recipients | Merck Sharp & Dohme Corporation | $13,767 | 0 |
| A Single Dose Trial to Assess the Effect of MK-8228 letermovir on QTc Interval in HealthyAdult Volunteers | Merck Sharp & Dohme Corporation | $1,931 | 0 |
| A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety andEfficacy of MK-8228 Letermovir for the Prevention of Clinically Significant HumanCytomegalovirus CMV Infection in Adult, CMV-Seropositive Allogeneic HematopoieticStem Cell Transplant Recipients | Merck Sharp & Dohme Corporation | $200.00 | 0 |
Top Doctors Receiving Payments for MK-8828
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Duarte, CA | $212,643 | 26 |
| , MD | Infectious Disease | Omaha, NE | $375.00 | 1 |
Manufacturing Companies
- Merck Sharp & Dohme Corporation $213,018
Product Information
- Type Drug
- Total Payments $213,018
- Total Doctors 1
- Transactions 27
About MK-8828
MK-8828 is a drug associated with $213,018 in payments to 1 healthcare providers, recorded across 27 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2018. In 2018, $195,512 was paid across 23 transactions to 0 doctors.
The most common payment nature for MK-8828 is "Unspecified" ($212,643, 99.8% of total).
MK-8828 is associated with 7 research studies, including "A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients" ($141,018).